Programmable CRISPR-Cas RNA gene circuits for translational theranostics
RNA molecules carry dynamic cellular and pathological information, making them ideal biomarkers for precision medicine. However, conventional RNA diagnosis and therapy operate independently without coordinated signal perception and responsive intervention. RNA-targeting CRISPR-Cas systems, especially Cas13 effectors, enable programmable transcriptome recognition and manipulation without permanent genomic modification. Synthetic CRISPR-based gene circuits integrate RNA sensing, molecular computation and therapeutic execution into one unified platform, bridging the gap between molecular detection and precision treatment. CRISPR-Cas technologies have expanded from programmable RNA recognition and editing tools into increasingly sophisticated platforms for RNA sensing, molecular computation, and therapeutic regulation. This review provides a comprehensive mechanistic and translational synthesis of CRISPR-Cas-based RNA gene circuits, with emphasis on the distinction between individual RNA-targeting components and integrated sensing–computation–actuation architectures. We examine major circuit designs, RNA-responsive logic, therapeutic applications, delivery strategies, circuit-level constraints, safety considerations, and the current experimental and translational evidence. Here, we provide a comprehensive narrative synthesis of the molecular mechanisms, circuit architectures, experimental implementations, delivery strategies, safety considerations, and translational challenges associated with CRISPR-Cas-based RNA gene circuits. By distinguishing component-level technologies from integrated RNA-responsive circuits and separating cell-free, cellular, organoid, animal, and clinical evidence, this review highlights both the capabilities and current limitations of the field. Finally, it outlines future prospects for developing clinically deployable RNA theranostic platforms, emphasizing optimized delivery systems, robust circuit design and rigorous preclinical validation in physiologically relevant disease models.
Authors
- Fu Wang (ORCID: https://orcid.org/0000-0001-9615-1038)
- Wajahat Ali
- Zhenlong Wang
- Kulsoom
Institutions
- Second Affiliated Hospital of Xi'an Jiaotong University (CN)
- Shaanxi Institute of International Trade & Commerce (CN)
- Xi'an Jiaotong University (CN)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2026-11-14
- DOI
- https://doi.org/10.1186/s12967-026-09215-6
- Primary Topic
- CRISPR and Genetic Engineering
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China